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combination with insulin versus insulin alone for patients who are inadequately 
controlled despite high doses of insulin. Methods: The published and vali-
dated CARDIFF diabetes model was used to conduct the analysis. Clinical inputs 
were derived from a randomized clinical trial comparing dapagliflozin add-on to 
insulin with insulin regimens. Based on clinical inputs and the United Kingdom 
Prospective Diabetes Study (UKPDS) equations, the model predicts disease pro-
gression and the number of micro- and macro-vascular complications, along with 
diabetes-specific and all-cause mortality. The perspective of the National Health 
Service in England and Wales was adopted over a lifetime horizon. Local unit 
costs and utility data were assigned to the appropriate model parameters to cal-
culate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
insulin, dapagliflozin added to insulin was associated with 0.342 incremental 
QALYs (95%CI: 0.288; 0.480) at an additional cost of £1,813 (95%CI: £1,165; £2,381), 
resulting in an incremental cost-effectiveness ratio (ICER) point estimate of 
£5,295 per QALY gained. The univariate analyses showed that no input 
parameter change inflated the ICER above £15,000 per QALY. At a willingness-to-
pay threshold of £20,000 per QALY gained, the dapagliflozin treatment strategy 
was estimated to have a 100% probability of being cost-effective when compared 
to the insulin treatment strategy. These findings were shown to be robust with all 
sensitivity analyses. ConClusions: Dapagliflozin was shown to be a cost-effec-
tive treatment option in combination with insulin for patients who are inad-
equately controlled with insulin alone within established UK cost-effectiveness 
thresholds.
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objeCtives: To evaluate uncertainty, the NICE reference case requires estimation 
of cost-effectiveness using alternative parameter values. Because models of T2DM 
necessarily include many parameters, NICE requirements dictate a large number 
of simulations. This study assesses the relative importance of common sensitivity 
analyses by identifying key drivers of the incremental cost-effectiveness ratio (ICER) 
using the example of CANA 300mg versus GLIM (titrated from 1mg to 6mg or 8mg), 
in combination with metformin in dual therapy. Methods: The ECHO-T2DM model 
was used to simulate CANA versus GLIM over 40 years. ECHO-T2DM was loaded 
with patient characteristics, treatment effects, and adverse event rates from the 
DIA3009 trial. HbA1c was assumed to drift annually by 0.14% for CANA (similar to 
metformin in ADOPT), 0.24% for GLIM (as sulphonylurea in ADOPT), and 0.15% for 
rescue therapy with insulin (initiated when HbA1c > 7.5%). Twenty-four one-way 
sensitivity analyses assessed the impact of drug durability, macrovascular risk equa-
tions, utility weights, and HbA1c goals. Results: In the base case, CANA 300mg 
was associated with 0.21 greater QALYs at an incremental cost of £828, generating 
an ICER of £4,050/QALY. QALY gains were driven by fewer hypoglycaemic events 
and a better weight profile. The low acquisition cost of GLIM was partially offset by 
a greater need for insulin rescue therapy earlier in treatment, more hypoglycaemic 
events, and more macrovascular complications. Assuming no difference in durabil-
ity for CANA and GLIM had the greatest impact on the ICER (£49,717), followed by 
no disutility for hypoglycaemic events (£15,733). The only other scenario having a 
noticeable impact was an HbA1c goal of 9.0% (£9,718). Alternative macrovascular 
risk engines had little impact on the ICER. ConClusions: The ICER was robust 
under a large number of scenarios. Only the difference in assumed long-term GLIM 
durability reversed the interpretation of CANA as cost-effective versus GLIM using 
NICE criteria.
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objeCtives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, including: 
life extension, micro- and macrovascular events, treatment and treatment-related 
adverse events (AEs), and excess bodyweight. This analysis aims to determine which 
factors most impact QALY gains using the example of CANA 300mg versus GLIM 
(titrated from 1mg to 6mg or 8mg) when combined with metformin. Methods: The 
ECHO-T2DM model was used to simulate CANA versus GLIM over 40 years. ECHO-
T2DM was loaded with patient characteristics, treatment effects, and AE rates from 
the DIA3009 trial. HbA1c was assumed to drift upwards at an annual rate of 0.14% 
for CANA (similar to metformin in the ADOPT trial) and 0.24% for GLIM (as sulpho-
nylurea in ADOPT). CANA and GLIM were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/mol 
(7.5%). Results: Hypothetical patients experienced 0.21 more QALYs when treated 
with CANA 300mg versus GLIM. Because GLIM was associated with greater use of 
rescue medication (and extra insulin-mediated HbA1c lowering) in the simulation, 
HbA1c values converged asymptotically limiting the differences in microvascular 
complications. However, lower blood pressure for patients on CANA versus GLIM was 
associated with reductions of 2.2% to 4.1% for the rates of macrovascular outcomes 
(although associated QALY gains were small due to discounting). Differences in weight 
and especially hypoglycaemic events, related both to GLIM and to earlier initiation of 
insulin, were associated with improvements in utility (0.04 and 0.16 QALYs, respec-
vascular events, but substantial benefits attributable to weight (0.020) and especially 
hypoglycaemic events (0.024), related to CANA’s better weight-lowering and longer 
time to initiation of insulin. ConClusions: Patients treated with CANA in triple 
therapy experienced an additional 0.039 QALY’s over 40 years versus patients treated 
with SITA. The primary drivers were improved weight while on agent and fewer 
hypoglycaemic events.
PDB56
the Cost-effeCtiveness of DAPAgliflozin (forxigA®) versus gliPiziDe 
in the treAtment of tyPe 2 DiABetes mellitus (t2Dm) in englAnD AnD 
WAles
Charokopou M.1, McEwan P.2, Lister S.3, Callan L.4, Bergenheim K.5, Tolley K.6, Roudaut M.7
1Pharmerit International, Rotterdam, The Netherlands, 2HEOR Consulting, Monmouth, UK, 
3Bristol-Myers Squibb, Uxbridge, UK, 4AstraZeneca UK Ltd., Luton, UK, 5AstraZeneca, Mölndal, 
Sweden, 6Tolley Health Economics, Buxton, UK, 7Bristol-Myers Squibb, Rueil-Malmaison, France
objeCtives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus. This study investigates the cost-effectiveness of dapagliflo-
zin compared with a sulphonylurea (SU) when added to metformin in patients 
inadequately controlled with metformin mono-therapy. Methods: The published 
and validated CARDIFF diabetes model was used to conduct the analysis. Clinical 
inputs were derived from a randomized clinical trial comparing dapagliflozin and 
glipizide in combination with metformin. Based on these clinical inputs and the 
United Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts 
disease progression and the number of micro- and macro-vascular complications, 
along with diabetes-specific and all-cause mortality. The perspective of the National 
Health Service in England and Wales was adopted over a lifetime horizon. Local 
unit costs and utility data were assigned to the appropriate model parameters to 
calculate total Quality-Adjusted-Life-Years (QALYs) and total costs. Univariate and 
probabilistic sensitivity analyses (PSA) were conducted. Results: Compared to 
SU added to metformin, dapagliflozin add-on to metformin was associated with 
an incremental benefit of 0.467 QALYs (95%CI: 0.420; 0.665) at an additional cost of 
£1,246 (95%CI: £613; £1,637), resulting in an ICER point estimate of £2,671 per QALY 
gained. The univariate analyses showed that no input parameter change inflated the 
ICER above £15,000 per QALY. The PSA showed that at a willingness-to-pay threshold 
of £20,000 per QALY gained, dapagliflozin treatment had an estimated 100% prob-
ability to be cost-effective compared to an SU treatment strategy. These findings 
were shown to be robust with all sensitivity analyses. ConClusions: Dapagliflozin 
in combination with metformin was shown to be a cost-effective treatment option 
for patients who are inadequately controlled with metformin mono-therapy within 
established UK cost-effectiveness thresholds.
PDB57
Cost-effeCtiveness of DAPAgliflozin As ADD-on to insulin for the 
treAtment of tyPe 2 DiABetes in the netherlAnDs
van Haalen H.G.M.1, Pompen M.2, Bergenheim K.3, McEwan P.4, Townsend R.5, Roudaut M.6
1AstraZeneca, Zoetermeer, The Netherlands, 2Bristol-Myers Squibb, Woerden, The Netherlands, 
3AstraZeneca, Mölndal, Sweden, 4Swansea University, Cardiff, UK, 5AstraZeneca, Brussels, 
Belgium, 6Bristol-Myers Squibb, Rueil-Malmaison, France
objeCtives: Insulin, often combined with metformin, is usually the last therapy 
option for patients with type 2 diabetes Mellitus (T2DM) who are uncontrolled on 
oral anti-diabetic drugs. Dutch guidelines recommend up-titration of insulin until 
patients maintain an HbA1c < 7%, yet in practice many patients never reach this tar-
get. Clinical evidence shows that dapagliflozin – a highly selective sodium-glucose 
cotransporter 2 (SGLT2) inhibitor – meets a need for these patients, i.e. by reduc-
ing HbA1c and weight. We studied the cost-effectiveness of dapagliflozin added to 
insulin (vs. not adding dapagliflozin) for patients with T2DM who have inadequate 
glycaemic control while on insulin. Methods: We used the Cardiff Diabetes model 
to evaluate cost and effects of dapagliflozin added to insulin using direct compara-
tive efficacy data from a randomized placebo-controlled trial (NCT00673231). In this 
trial up-titration of insulin was allowed in case of severe glycaemic imbalance. Risk 
factor progression and occurrence of future vascular events were estimated using 
the UKPDS 68 risk equations. Costs and utilities were derived from the literature. 
The analysis was conducted from a Dutch societal perspective using a lifetime hori-
zon. Results: The overall incidence of vascular complications was lower, and life 
expectancy was higher (19.43 LYs vs. 19.35 LYs) in those patients receiving dapagli-
flozin compared to patients not receiving dapagliflozin. Patients in the dapagliflozin 
arm obtained an incremental benefit of 0.42 QALYs. The lifetime incremental cost 
per patient in the dapagliflozin arm was € 2,293, resulting in an incremental cost-
effectiveness ratio of € 27,779 per LYG and an incremental cost-utility ratio of € 5,502 
per QALY gained. Sensitivity and scenario analyses showed that the results were 
robust to variation in modelling assumptions and input variables. ConClusions: 
This analysis shows that dapagliflozin increases the quality of life of T2DM patients 
compared to current practice (up-titration of insulin), and is cost-effective in a 
Dutch health care setting.
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objeCtives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
(SGLT-2) inhibitor approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 2 
diabetes mellitus. This study assesses the costs-effectiveness of dapagliflozin in 
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discounted at 5% annually. Sensitivity analyses were performed. Results: Fenofibrate 
monotherapy improved mean quality-adjusted life expectancy by 0.09 QALYs versus 
placebo due to fenofibrate patients spending more time in mild DR states. Direct medi-
cal costs were AUD 898 higher for fenofibrate monotherapy, with additional treatment 
costs partially offset by reduced cost associated with advanced DR (e.g. ophthalmolo-
gist time and laser treatment), leading to an ICER of AUD 10,221 per QALY gained. 
Similarly, fenofibrate+statin led to an improvement of 0.05 QALYs versus statin alone 
with an incremental direct cost of AUD 1,707. The ICER for fenofibrate+statin was AUD 
33,350 per QALY gained versus statin alone. Sensitivity analysis showed that results 
were relatively insensitive to changes in a range of assumptions. ConClusions: The 
reduced risk of DR progression associated with fenofibrate treatment was projected 
to improve quality-adjusted life expectancy, with treatment costs partially offset by 
reduced costs of retinopathy care. ICERs indicated that fenofibrate therapy was in the 
range likely to be considered cost-effective in Australia.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for the management of patients with type 1 (T1DM) and patients 
with type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose con-
trol with less hypoglycaemic events and with an option for flexibility in dose time 
compared to insulin glargine (IGlar). The aim of this analysis was to evaluate the 
cost-effectiveness of IDeg versus IGlar in adults with T1DM in the UK. Methods: 
Meta-analysis data from two phase III clinical studies were used to populate a 
simple, transparent short-term model. The analysis was conducted from the UK 
National Health Service perspective and costs and benefits were calculated over 
a 12-month period. Sensitivity analyses were conducted to assess the degree of 
uncertainty around the results. In order to test the robustness of the results, two 
versions of the model were used. One applied disutilities derived from the SF-36 
questionnaire used in the clinical trials, the other applied disutilities associated with 
the occurrence of hypoglycaemic events. In both approaches an additional utility 
gain was attributed to the benefit of dosing flexibility. Baseline incidence of hypogly-
caemia was taken from a real-life study from the UK. Resource use associated with 
hypoglycaemia was documented in the clinical trials. Published tariffs were used 
as unit costs. Results: The base-case ICERs were £12,637/QALY and £13,349/QALY 
in the two modelling approaches, which are below commonly accepted thresholds 
for cost-effectiveness. The results were robust and largely insensitive to changes in 
input parameters. ConClusions: This short-term modelling approach allows the 
economic evaluation of newer insulin analogues when advanced long-term model-
ling based on HbA1c differences is inappropriate due to the treat-to-target nature of 
the clinical trials resulting in equivalent HbA1c levels. For patients in the UK with 
T1DM IDeg is a cost-effective treatment option compared with IGlar.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long dura-
tion of action for management of patients with type 1 (T1DM) and patients with 
type 2 (T2DM) diabetes. IDeg has demonstrated effective blood glucose control with 
less hypoglycaemic events and an option for flexibility in dose time compared to 
insulin glargine (IGlar). The aim of this analysis was to evaluate the cost-effec-
tiveness of IDeg versus IGlar in adults with T2DM initiating insulin therapy in the 
UK. Methods: Meta-analysis data from three clinical studies were used to populate 
a 1-year cost-utility model. The analysis was conducted from the UK National Health 
Service perspective. Sensitivity analyses were conducted to assess the robustness 
of results. Two versions of the model were tested, one applied disutilities derived 
from the SF-36 questionnaire used in the clinical trials, the other applied disutili-
ties associated with the occurrence of hypoglycaemic events. In both approaches 
an additional utility gain was attributed to the benefit of dosing flexibility. Baseline 
incidence of hypoglycaemia was derived from a UK real-life study. Resource use 
associated with hypoglycaemia was documented in the clinical studies. Official 
tariffs were used as unit costs. Results: Base-case ICERs were £15,705/QALY and 
£13,003/QALY in the two modelling approaches. Results were robust, with baseline 
rate of hypoglycaemia a key driver of results. Using hypoglycaemia rates from a 
subgroup of patients who experienced ≥ 1 hypoglycaemic event per year IDeg was 
highly cost-effective versus IGlar; with estimated ICERS of £4,706/QALY and £2,528/
QALY. ConClusions: This short-term modelling approach allows the economic 
evaluation of newer insulin analogues when advanced long-term modelling based 
on HbA1c differences is inappropriate due to treat-to-target trial design. For patients 
with T2DM on a basal-only insulin regimen, IDeg is cost-effective compared with 
IGlar and offers additional benefits to subgroups of patients, such as those suffering 
from recurrent hypoglycaemia.
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tively). ConClusions: Patients treated with CANA in dual therapy experienced an 
additional 0.21 QALYs over 40 years versus patients treated with GLIM. The primary 
drivers were improved weight while on agent and fewer hypoglycaemic events.
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objeCtives: In Poland, where long acting insulin analogues (LAA) are not currently 
reimbursed in T2DM, it is crucial to select a group of patients for whom LAA may 
be particularly preferred. Based on NICE recommendation such patients are those 
treated with human insulin (NPH) but not achieving glycaemic control. Thus the aim 
of this study was to evaluate the cost-effectiveness of insulin detemir (IDet) when 
compared to NPH in subpopulation of poorly controlled T2DM as defined by HbA1c 
≥ 8% and/or ≥ 1 episode of severe or nocturnal hypoglycemia recorded during ≥ 6 
months of NPH treatment. Methods: A validated computer simulation of diabetes 
model (IMS-CORE) was used to project long-term clinical and economic outcomes. 
Clinical effects in HbA1c improvement, BMI change and reduction in hypoglycemic 
episodes were modelled. Analysis was based on findings from the subgroups of the 
PREDICTIVE study – a real-world data trial – that closely reflects the defined target 
population. Two distinct insulin therapy regimens with IDet and NPH were evalu-
ated: basal-supported oral therapy (BOT) and a basal-bolus (BB) regimen. Baseline 
cohort characteristics, disease progression and utility estimates were obtained from 
systematic literature review. Costs were obtained from Polish published data. The 
analysis was conducted from a public payer and patient perspective over a lifetime 
time horizon. Discount rates were 5% (costs) and 3.5% (outcomes). Results: The 
mean QALY gain resulting from treatment initiation with IDet compared with NPH 
was 0,311 (BOT) and 0,451 (BB). Base-case incremental cost-effectiveness ratios 
(ICERs) were 38,136 PLN/QALY (9,113€ ) and 13,726 PLN/QALY (3,280€ ), respectively. 
At the current ICER threshold of 105,801 PLN/QALY (25,281€ ) in Poland, probability 
of IDet being cost-effective compared to NPH is 95% (BOT) and approaching 100% 
(BB). ConClusions: Based on generally accepted cost/QALY threshold values in 
the Polish settings, IDet was found to be a cost-effective option for T2DM patients 
with inadequately controlled diabetes.
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objeCtives: Insulin degludec (IDeg) is a basal insulin with an ultra-long duration 
of action for management of patients with type 1 (T1DM) and patients with type 
2 (T2DM) diabetes. IDeg have demonstrated efficacious blood glucose control with 
less hypoglycaemic events and with an option for flexibility in dose time compared 
insulin glargine (IGlar). The objective was to assess the cost-effectiveness of IDeg in 
Spain, compared with IGlar. The analysis focused on subgroups of patients within 
three treatment regimens: T1DM, T2DM treated with basal insulin in combination 
with oral anti-diabetics (BOT) and T2DM treated with basal-bolus (BB). Methods: 
A one-year cost-utility model driven by differences in hypoglycaemia was used. Two 
alternative utility approaches were used: in the first case, the utility gain was elicited 
from the clinical trials. In the second, published dis-utilities for hypoglycaemic 
events and self-monitoring blood glucose tests were used to calculate QALYs. Cost 
and utilities were also estimated for potential use of less blood glucose test strips. 
Three subgroups were analysed: those using twice daily IGlar, those with high risk 
of severe hypoglycaemia, and those obtaining extra utility from dosing flexibility. 
Unit costs pertained to public tariffs and reflected the payer perspective. Baseline 
incidence rates of hypoglycaemia and related resource use was derived from a 
Spanish observational study. Results: IDeg was dominant for T1DM, T2DM BOT 
and T2DM BB switching from twice daily. T2DM BOT with high risk of hypoglycaemia 
was also dominant. As for patients benefiting from dosing flexibility the cost/QALY 
were 6,921€ /QALY in T1DM, 9,244€ /QALY in T2DM BOT, and 33,099€ /QALY in T2DM 
BB. The use of the two different utility methods gave similar results. Univariate and 
probabilistic sensitivity analyses confirmed robust results. ConClusions: This 
analysis demonstrates that IDeg is a cost-effective option in Spain, when used in 
sub-groups of patients currently treated with long-acting insulin.
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objeCtives: Evidence from the landmark trials FIELD and ACCORD demonstrated 
that fenofibrate significantly reduces rates of diabetic retinopathy (DR) progression 
in type 2 diabetes patients (T2DM). This study evaluates the long-term cost-effective-
ness of fenofibrate mono- and combination therapy for DR in Australia. Methods: A 
seven-state Markov model simulated progression of DR based on data from the Blue 
Mountain Eye Study. Risk reductions for retinopathy progression were derived from 
FIELD for fenofibrate monotherapy (vs. placebo) and ACCORD for fenofibrate+statin 
(vs. statin alone). No additional benefits were assumed beyond 5 years (DR progression 
was the same with/without fenofibrate after year 5). Quality-adjusted life expectancy, 
direct costs and incremental cost-effectiveness ratios (ICERs) were reported over 10 
years. Unit costs (2012 Australian dollars, AUD), resource use and utilities were taken 
from country-specific sources/expert opinion. Future costs and clinical benefits were 
